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Exosomes regulate cell behavior by binding to and delivering
their cargo to target cells; however, the mechanisms mediating
exosome-cell interactions are poorly understood. Heparan sul-
fates on target cell surfaces can act as receptors for exosome
uptake, but the ligand for heparan sulfate on exosomes has not
been identified. Using exosomes isolated from myeloma cell
lines and from myeloma patients, we identify exosomal
fibronectin as a key heparan sulfate-binding ligand and media-
tor of exosome-cell interactions. We discovered that heparan
sulfate plays a dual role in exosome-cell interaction; heparan
sulfate on exosomes captures fibronectin, and on target cells it
acts as a receptor for fibronectin. Removal of heparan sulfate
from the exosome surface releases fibronectin and dramatically
inhibits exosome-target cell interaction. Antibody specific for
the Hep-II heparin-binding domain of fibronectin blocks exo-
some interaction with tumor cells or withmarrow stromal cells.
Regarding exosome function, fibronectin-mediated binding of
exosomes to myeloma cells activated p38 and pERK signaling
and expression of downstream target genes DKK1 andMMP-9,
two molecules that promote myeloma progression. Antibody
against fibronectin inhibited the ability of myeloma-derived
exosomes to stimulate endothelial cell invasion.Heparin orhep-
arin mimetics including Roneparstat, a modified heparin in
phase I trials in myeloma patients, significantly inhibited exo-
some-cell interactions. These studies provide the first evidence
that fibronectin binding to heparan sulfate mediates exosome-
cell interactions, revealing a fundamental mechanism impor-
tant for exosome-mediated cross-talk within tumor microenvi-
ronments. Moreover, these results imply that therapeutic
disruption of fibronectin-heparan sulfate interactions will neg-
atively impact myeloma tumor growth and progression.
Multiple myeloma remains incurable, despite recent treat-
ment advances (1). There is mounting evidence that targeting
intercellular communication between malignant plasma cells
or between malignant cells and host cells may enhance thera-
peutic outcome. Extracellular vesicles, because they can
directly interact with target cells, have emerged as important
mediators of intercellular communication. Exosomes are a type
of extracellular vesicle derived from endosomes and released by
cells into the extracellular space. Exosomes are generally char-
acterized by their size (ranging from 30 to 150 nm) and
expression of certain surface markers. However, at present
there are no markers specific for exosomes (2). Several studies
have shown that these exosome-like particles secreted by
tumor cells can affect survival, apoptosis, invasion, angiogene-
sis, resistance to therapy, and premetastatic niche formation
(3–6). Exosomes influence these processes bymediating signal-
ing at the cell surface and by facilitating the intercellular trans-
fer of tumor-derived proteins and nucleic acids. Recent studies
have demonstrated critical roles for myeloma-derived exo-
somes in mediating intercellular communication and promot-
ing myeloma progression (7–9). For example, myeloma cell-
derived exosomes can promote the formation and function of
osteoclasts and thereby stimulate osteolysis (7). Another study
showed that exosomal microRNA 135b released by hypoxic
multiplemyeloma cells enhances angiogenesis by targeting fac-
tor inhibiting hypoxia-inducible factor 1 (8). In addition, we
recently discovered that exosomes secreted by aggressive
myeloma cells can induce tumor cell spreading and endothelial
cell invasion (9).
Heparan sulfate proteoglycans are glycoproteins that contain
a core protein with one or more covalently attached negatively
charged heparan sulfate glycosaminoglycan chains. Heparan
sulfate chains can bind and regulate the function of a wide vari-
ety of adhesion molecules, cytokines, growth factors, chemo-
kines,morphogens, various types of viral particles, lipoproteins,
etc. (10). By interacting with various cell adhesion receptors
and extracellular matrix proteins such as fibronectin and colla-
gens, heparan sulfate chains promote cell-cell and cell-ECM
interactions (10). Although the functional effects of exosomes
rely on their interaction with, and subsequent delivery of their
cargo to target cells, the mechanisms mediating exosome-cell
interactions remain unclear. Studies have shown that heparin
can block interactions between extracellular vesicles and cells
and that heparan sulfate proteoglycans on glioblastoma cells
facilitates extracellular vesicle uptake (11–14). This uptake was
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blocked by the addition of exogenous heparin (a highly sulfated
glycosaminoglycan mimetic of heparan sulfate), which can
compete with cell surface heparan sulfate to bind exosomes.
However, the receptor on the exosome surface that binds to
heparan sulfate on the target cell has not been identified.
In the present study, we discovered that fibronectin on the
exosome surface mediates the interaction with heparan sulfate
chains on target cells. Fibronectin is a high affinity ligand for
heparin/heparan sulfate and contains a strong heparin/heparan
sulfate binding site, designated Hep-II, located within the
C-terminal repeat units 12–14 of fibronectin (15). Several stud-
ies have shown that binding of cell surface heparan sulfate pro-
teoglycans such as syndecans to the heparin-binding domain
on fibronectin or to a synthetic peptide corresponding to this
domain induces the formation of stress fiber, focal adhesion
kinase, and cell spreading (16–18). We demonstrate that
myeloma-derived exosomes have fibronectin bound on their
surface and that, via its Hep-II domain, fibronectin facilitates
exosome interactionwith heparan sulfate chains present on the
surface of target cells. Additionally, we show that fibronectin is
bound to exosome surface via interacting with heparan sulfate
chains on the exosome surface. These findings provide the first
evidence that fibronectin present on the surface of tumor-de-
rived exosomes facilitates exosome-target cell interaction and
reveal a novel mechanism whereby the heparan sulfate pro-
teoglycans present on exosomes and on target cells can influ-
ence exosome-mediated intercellular communication.
Experimental Procedures
Cell Lines—RPMI-8226 andCAGhumanmyeloma cells were
cultured as described previously (19). Aggressive (heparanase-
high) and less aggressive (heparanase-low) control CAG cells
were selected as described previously (20). For preparing cells
to secrete fluorescent exosomes, CAG cells were infected with
lentivirus particles packaged with pCT-CMV vector encoding
CD63 tetraspanin-red fluorescent protein (RFP)3 fusion pro-
tein (System Biosciences). Infected cells were selected using
puromycin. Human bone marrow stromal cell line HS-5 and
human umbilical vein endothelial cells were maintained as
described previously (21).
Exosome Isolation from Cell Culture Supernatants and
Myeloma Patient Serum—Human myeloma cells growing in
culture were washed twice with PBS and grown in serum-free
medium for 24–42 h. As previously described, exosome-like
particles secreted into the medium by CAG myeloma cells
were isolated by differential centrifugation, characterized by
surface marker expression and size, and found to be consistent
with the characteristics of exosomes (9). Particle size was mea-
sured by nanoparticle tracking analysis using a NanoSight 300
(Malvern Instruments Ltd.). For mass spectrometry and flow
cytometry analyses, 800 g of exosomes obtained by ultracen-
trifugation were layered on the top of a 40% iodixanol cushion
(Sigma) and centrifuged for 16 h at 28,000 rpm. The remaining
exosome fraction excluded by the cushionwas pelleted by ultra-
centrifugation at 100,000 g for 70 min and used for analysis.
Exosomes were quantified by nanoparticle tracking analysis or
bymeasuring the protein using a BCAprotein assay kit (Pierce).
Serum samples were obtained from treatment naïvemultiple
myeloma patients enrolled in the Molecular and Genetic Epi-
demiology (iMAGE) study ofmyelomawhomet the revised and
updated InternationalMultipleMyelomaWorkingGroup clas-
sification criteria for myeloma (22). Approvals from the appro-
priate Institutional Review Boards were obtained prior to study
initiation. Exosomes were isolated from serum using an Exo-
Quick isolation kit (System Biosciences). Briefly, to 100 l of
serum, 30 l of ExoQuick solution was added and incubated at
4 °C for 1 h and then centrifuged at 1500  g for 30 min. The
pellet was resuspended in PBS, and the exosomes were further
purified using anit-CD63 conjugated to magnetic beads (Sys-
temBiosciences), according to themanufacturer’s instructions.
Particle size and number was assessed using NanoSight 300.
The capture settings and analysis settings were performed
manually according to the manufacturer’s instructions. For
some experiments, exosomes were fluorescently labeled using
PKH67 (green) or PKH26 (red) (Sigma), according to the man-
ufacturer’s recommendation, followed by extensive washing to
remove residual lipid dye.
Flow Cytometry Analysis of Exosomes Bound to Beads—Flow
cytometry analysis to identify molecules on the surface of exo-
somes was performed after attaching exosomes to either anti-
CD63-bound beads or heparin-agarose beads (MP Biomedicals
Inc.). 100 g of purified exosomes were mixed with the anti-
CD63 beads or heparin agarose beads and incubated on a rotat-
ing rack at 4 °C overnight. Exosomes bound to beads were sus-
pended in 200 l of 1% BSA in PBS and stained with antibodies
against fibronectin or syndecan-1 prior to analysis with a Bec-
tonDickinson FACSCalibur flow cytometer located in theUAB
Comprehensive FlowCytometry Core. Fibronectin was stained
using a mouse monoclonal anti-human fibronectin-PE-conju-
gated antibody (R&D Systems). Mouse isotype matched (IgG1)
PE (Thermo Fisher) was used as the control. For detection of
syndecan-1, exosomes bound to anti-CD63 beads were treated
with bacterial heparitinase (Seikagaku) for 2 h at 37 °C followed
by extensive washing. This enzyme treatment, by releasing
heparan sulfate and any bound ligands (e.g. fibronectin),
exposes the core protein epitope to the antibody. Syndecan-1
was detected using an affinity-purified polyclonal goat anti-
syndecan-1 IgG (R&D Systems) and PE-conjugated secondary
antibody. Normal goat IgG was used for the control (Santa
Cruz).
Exosome Protein Analysis by MS/MS—Exosomes excluded
by an iodixanol cushion were solubilized in 1 LDS sample
buffer (NuPAGE; Life Technologies) followed by membrane
disruption for 10min in anultrasonic bath (ThermoFisher) and
heat denaturation as per manufacturer’s instructions for the
LDS buffer. Protein extracts were then quantified using the
BCA protein assay kit (Pierce, Life Technologies). An aliquot
containing 20g of proteinwas reduced, denatured, and loaded
onto a 10% Bis-Tris gel (NuPAGE reagents; Life Technologies)
and separated as a short stack run (1 cm). The gel was stained
with a colloidal blue staining kit (NuPAGE, Life Technologies),
destained, and visualized. The upper gel section containing
protein for each sample was cut out and digested using Trypsin
3 The abbreviations used are: RFP, red fluorescent protein; MMP, matrix met-
alloproteinase; PE, phycoerythrin.
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Gold (Promega), followed by peptide extraction as per theman-
ufacturer’s instructions, and the volumes were reduced using a
Savant SpinVac Concentrator (Thermo Fisher). One micro-
gram of peptide extract (diluted to1 g/10 l in 0.1% formic
acid) was loaded onto a 100 m  13-cm capillary column,
packed in-house with C18 Monitor 100 A-spherical silica
beads, and eluted over a 90-min gradient (0–30% acetonitrile in
0.1% TFA). Liquid chromatography mass spectrometric analy-
sis was performed in duplicate using an LTQ Velos Pro
Orbitrap (Thermo Fisher), and data were analyzed within the
University of Alabama at Birmingham Comprehensive Cancer
Center Mass Spectrometry/Proteomics Shared Facility as pre-
viously described (23).
Analysis of Exosome-Cell Interactions—Subconfluent RPMI-
8226 myeloma cells or HS-5 bone marrow stromal cells were
incubated with CD63-RFP or PKH-labeled myeloma-derived
exosomes (100g/ml) for 2 h. The cellswerewashed in PBS and
fixed in 3% paraformaldehyde for 15 min on ice. Myeloma cells
grow in suspension and thereforewere cytospun on to slides for
analysis. All samples were analyzed using a Nikon A1 confocal
microscope. Fluorescent exosomes bound to cells were quanti-
fied by flow cytometry using a FACSCalibur instrument. For
experiments designed to block the Hep-II domain of fibronec-
tin on exosomes, the exosomes were preincubated with mono-
clonal antibody (A32) (25 g of antibody/100 g of exosome)
that binds specifically to the Hep-II heparin-binding domain of
fibronectin (Thermo Fisher). For experiments designed to
block heparan sulfate on the surface of target cells, the cells
were incubated with a 40-kDa fragment of human fibronectin
(purified from chymotryptic digest of human plasma fibronec-
tin) that contains the Hep-II binding domain (50 g/ml) (Mil-
lipore). After washing to remove unbound fibronectin frag-
ments, exosome-target cell interaction was analyzed by
confocal microscopy or flow cytometry. For experiments in
which heparan sulfatewas removed fromcell surface, cells were
treated with 5 millunits/ml of bacterial heparitinase for 2 h at
37 °C, followed by extensive washing. For removing heparan
sulfate from exosomes, 100 g of exosomes were treated with
1.5 millunits/ml heparitinase for 3 h at 37 °C; new enzyme was
added, and exosomes were incubated overnight. Exosomes
were then pelleted by ultracentrifugation to remove enzyme. In
some blocking experiments, exogenous heparin (10 g/ml),
Roneparstat (10 g/ml), or a synthetic heparin dodecasaccah-
ride (100g/ml) was added simultaneously with 100g of exo-
somes/ml. Roneparstat (previously known as SST0001) is a pro-
prietary drug of Sigma-Tau Research Switzerland that inhibits
growth of myeloma tumors in animal models (24) and is cur-
rently in phase I trials in advanced multiple myeloma patients
(ClinicalTrials.gov identifier NCT01764880). The heparin
dodecasaccharide is a fully sulfated molecule prepared by che-
moenzymatic synthesis (25).
Fibronectin ELISA—Fibronectin levels were quantified using
a commercially available human fibronectin ELISA kit (Milli-
pore), according to themanufacturer’s protocol. The assay is in
the format of competitive inhibition ELISA. For some experi-
ments, exosomes were treated without or with 1.5 millunits/ml
heparitinase for 3 h at 37 °C followed by the addition of fresh
enzyme and incubation overnight. Exosomeswere thenwashed
and pelleted by ultracentrifugation or ExoQuick exosome pre-
cipitation solution. Exosome protein content of the various
samples was determined by BCA protein assay, and an equal
amount of exosome protein (8 g) from each sample was used
for the ELISA.
Western Blot—100 g of exosomes, based on BCA protein
assay, were lysed in RIPA buffer containing protease inhibitors
for 10 min on ice, and proteins were separated by electropho-
resis in a 4–12% SDS-PAGE. The proteins were electroblotted
to nitrocellulose membrane and probed with primary antibod-
ies that recognize fibronectin (R&D Systems), clathrin
(Abcam), or flotillin (Abcam). In some experiments, the exo-
somes were treated with bacterial heparitinase and probed for
syndecan-1 (R&D Systems). Primary antibodies were detected
using HRP-conjugated secondary antibodies, and bands were
visualized by chemiluminescence. In some experiments, RPMI-
8226 cells were treated with or without heparitinase for 2 h at
37 °C and then exposed to 100 g/ml of either control or
aggressive exosomes for 20min. Cells were lysed andprobed for
phosphorylated p38 or total p38 (Cell Signaling).
Real Time PCR—RNA was isolated from CAG human
myeloma cells incubated with or without exosomes, and real
time PCR was conducted for MMP-1 and DKK1 using SYBER
Green supermix (Bio-Rad). mRNA expression was determined
relative to actin.
Human Phosphokinase Array—Amembrane-based antibody
array (R&D Systems) that determines the relative levels of 43
different human phosphorylated protein kinases was utilized
according to the manufacturer’s instructions. Briefly, equal
amounts of cell lysates of human RPMI-8226 cells treated with-
out or with 100 g of exosomes were incubated overnight with
the phosphokinase array membrane. The array was washed to
remove unbound proteins followed by incubation with a mix-
ture of biotinylated detection antibodies. Streptavidin-HRP
and chemiluminescent detection reagents were applied to visu-
alize the signal produced at each capture spot corresponding to
the amount of phosphorylated protein bound.
Endothelial Cell Invasion—The effect of exosomes on the
invasion of human umbilical vein endothelial cells was assessed
using Biocoat Matrigel invasion chambers (BD Biosciences), as
described (9). To study the relevance of fibronectin-heparan
sulfate interactions for the functional activity of exosomes, exo-
somes were preincubated without or with the anti-fibronectin
antibody A32 (25 g of antibody/100 g of exosome protein)
before adding to the endothelial cells.
Results
Fibronectin Is Present on the Surface of Myeloma-derived
Exosomes and Enhances Exosome-Cell Interactions—Expres-
sion of the heparan sulfate degrading enzyme heparanase in
CAG human myeloma cells reprograms them toward a highly
aggressive phenotype in vivo endowing tumors formed by these
heparanase-high cells with increased metastasis, angiogenesis,
and osteolysis comparedwith control, heparanase-low express-
ing cells (26–29). In analyzing exosomes from these aggressive
and control cells, we found those secreted by the aggressive
cells had higher levels of syndecan-1 (CD138), VEGF, and he-
patocyte growth factor and were able to promote tumor cell
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spreading and endothelial cell migrationmuch better than exo-
somes from control cells, which failed to substantially impact
cell behavior (9). To look for other exosomal proteins that reg-
ulate exosome function, we compared the protein content of
exosomes secreted by the aggressive versus control cells using
mass spectrometry. As expected, the level of heparanase
detected was much higher in exosomes secreted by the aggres-
siveCAGcells, whereas the level of immunoglobulin light chain
was identical in the exosomes secreted by control and aggres-
sive CAG cells (Fig. 1A). Interestingly, fibronectin was signifi-
cantly enhanced in abundance in exosomes from aggressive
cells compared with control cells. The presence of fibronectin
in exosomes was confirmed by Western blotting and ELISA
(Fig. 1, B and C).
Interaction of exosomes with target cells is a critical step in
the process of exosome-mediated intercellular communica-
tion. Because fibronectin is known to play an important role in
adhesion via interactions with integrins, collagens, fibrin, and
heparan sulfate proteoglycans, we hypothesized that it played a
role in exosome-cell interactions. First, to determine whether
the level of fibronectin on exosomes correlated with their abil-
ity to interact with target cells, we transfected the aggressive
and control CAG cells with a construct coding for a chimeric
protein composed of CD63 and red fluorescent protein (CD63-
RFP). CD63 is a tetraspanin protein that is abundant on the
exosomemembrane. Thus cells transfectedwith theCD63-RFP
secrete exosomes that can easily be tracked by fluorescence
microscopy. Interestingly, by both confocal microscopy and
flow cytometry, we found that the exosomes secreted by the
aggressive cells and containing high levels of fibronectin inter-
acted much better with target cells than did the exosomes hav-
ing low levels of fibronectin (Fig. 1, D and E). As shown in Fig.
1F, the RFP levels in the exosomes secreted by aggressive and
control cells were equivalent, thereby validating their use for
quantitative studies. Having established that exosomes having
high levels of fibronectin readily interact with target myeloma
cells, we utilized these exosomes in all the subsequent in vitro
studies to explore the role of fibronectin in exosome-cell
interactions.
In initial studies we assessed whether fibronectin was local-
ized to the exosome surface. For this, exosomeswere isolated by
centrifugation over an iodixanol cushion and bound to either
anti-CD63-containing magnetic beads (Fig. 2A, left panel) or
heparin-agarose beads (Fig. 2A, right panel), exposed to anti-
fibronectin antibody, and subjected to flow cytometry. The
results demonstrated that fibronectin is abundant on the exo-
some surface. Because fibronectin can bind to heparan sulfate
and because these exosomes from aggressive CAG cells have a
high level of the heparan sulfate-bearing proteoglycan synde-
can-1 on their surface (9), we speculated that fibronectin may
be bound to the exosome surface through its interaction with
heparan sulfate chains of syndecan-1. To test this, exosomes
FIGURE 1. Fibronectin is present on myeloma-derived exosomes, and a
high level of fibronectin correlates with enhanced exosome interaction
with target cells. A, result of a single mass spectrometry analysis of selected
exosomal proteins from human CAG control (heparanase-low) or aggressive
(heparanase-high) myeloma cells. Fibronectin was the protein most
enhanced in abundance in exosomes from aggressive cells compared with
control. B and C, the amounts of fibronectin associated with exosomes
secreted by control or aggressive CAG myeloma cells were quantified by
Western blot (B) and ELISA (C). The results aremeans S.D. of three indepen-
dent experiments. #, p 0.05 compared with control. Clathrin, a marker for
cell-derived vesicles, serves as the loading control for the Western blot. D, to
generate cells that secrete CD63-RFP exosomes, CAG control or aggressive
cells were transfected with a lentiviral vector coding for a CD63-RFP chimeric
protein. Exosomes (10 g/ml) secreted by these cells were incubated with
human RPMI-8226 myeloma cells. After 2 h, cells were washed, fixed with
3.7% formaldehyde, cytospun, and imaged by confocal microscopy. Red, RFP
exosomes; blue, nucleus. E, quantitative data from an experiment similar to
that shown inDwere obtained by subjecting the cells with bound exosomes
to flow cytometry. The data are presented as fold increase of median fluores-
cence intensity of cells incubated with exosomes as compared with cells not
incubated with exosomes and are mean  S.D. from three independent
experiments. *,p0.05. F, to ensure that the results inDandEabovewerenot
due to a higher per exosome concentration of CD63-RFP in the exosomes
secretedby aggressive cells, the RFP intensity of an equal amount (8 or 40g)
of exosomes (exo) with low (L) and high (H) levels of fibronectin was mea-
sured. The fluorescence intensity (excitation, 565 nm; emission, 610 nm) of
exosomes was equivalent. FN, fibronectin.
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were exposed to bacterial heparitinase, an enzyme that exten-
sively degrades the heparan sulfate chains of syndecan-1 on the
surface of these exosomes (Fig. 2B, right panel). Following the
removal of heparan sulfate from the exosome surface by hepa-
ritinase, the fibronectin remaining associatedwith the exosome
was greatly reduced (Fig. 2B, left panel). To determine whether
exosomes depleted of fibronectin from their surface affected
exosome-target cell interaction, CD63-RFP exosomes were
treated with heparitinase, pelleted to remove the enzyme, and
then incubated with RPMI-8226 myeloma cells. Fluorescence
microscopy and flow cytometry revealed that removal of
fibronectin from the exosome surface dramatically reduced
their binding to target cells compared with exosomes having
fibronectin on their surface (Fig. 2C). Together these results
indicate that fibronectin is present on the surface of exosomes,
it is retained there via interaction with heparan sulfate chains,
and its removal inhibits interaction of exosomes with target
cells.
Fibronectin on Exosomes Binds to Heparan Sulfate Chains on
Target Cells—It was previously demonstrated that exosomes
secreted by human glioblastoma cells interactwith heparan sul-
fate chains present on target cells (13). Based on this observa-
tion, we speculated that fibronectin, in addition to interacting
with heparan sulfate on the exosome surface, was also interact-
ing with heparan sulfate on the surface of target cells, thereby
serving as an adhesive “linker” between exosome and target
cells. This was first examined by incubating exosomes with
polarized or nonpolarized CAG myeloma cells; polarized cells
have heparan sulfate localized to the uropod of cells, and non-
polarized cells have heparan sulfate distributed over the cell
surface (19). Confocal microscopy revealed that the exosomes
bound to these cells in a pattern that mimicked this known
FIGURE 2. Fibronectin is present on the exosome surface and its removal inhibits exosome interactionwith target cells. A, fibronectin is present on the
surface of exosomes. Exosomes from aggressive CAG cells, purified by ultracentrifugation and excluded by an iodixanol cushion, were captured either using
anti-CD63 magnetic beads (left panel) or using heparin-agarose beads (right panel) and subjected to flow cytometry analysis using a mouse monoclonal
PE-conjugated anti-fibronectin antibody (blue histogram). PE-conjugated isotype-matched antibody was used as a control (orange histogram). B, removal of
heparan sulfate from the exosome surface removes most of the fibronectin associated with the exosome. Left panel, exosomes were either not treated or
treated with bacterial heparitinase (1.5 millunits/ml heparitinase for 3 h at 37 °C followed by addition of fresh enzyme and incubation overnight), a heparan
sulfate degrading enzyme, and fibronectin levels were quantified by ELISA. The data are expressed as means S.D. #, p 0.05 compared with exosomes not
treatedwith heparitinase. Right panel, Western blot for syndecan-1 on exosomes after heparitinase digestion. Flotillin, amarker for cell-derived vesicles, serves
as the loading control. C, depletion of heparan sulfate from exosomes decreases exosome-target cell interaction. CD63-RFP exosomes secreted by CAG cells
were either untreatedor treatedwith heparitinase andwashed, and their interactionswith RPMI-8226 cellswere analyzedby confocalmicroscopy.Right panel,
quantitative data from a similar experiment analyzed by flow cytometry. The results are expressed as fold change of themedian fluorescence intensity. #, p
0.05 compared with no heparitinase treatment.
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pattern of heparan sulfate localization (Fig. 3A). Treatment of
target cells with heparitinase prior to incubationwith exosomes
abolished exosome-cell interactions, thereby confirming a role
for cell surface heparan sulfate chains in binding to the exo-
somes (Fig. 3B).
Because disruption of exosome-target cell interaction could
be of therapeutic value, we tested whether heparin mimetics
would compete against exosome and/or cell surface heparan
sulfate and thereby disrupt the interaction. Twomimetics were
tested, a fully sulfated 12-mer oligosaccharide (that was gener-
ated by chemoenzymatic synthesis), and Roneparstat, which is
100% N-acetylated and 25% glycol split. Both mimetics inhib-
ited exosome-target cell interaction, as did heparin, the positive
control for the experiment (Fig. 3C). Although heparin and
Roneparstat were effective at a concentration of 10 g/ml, a
dose of 100g/ml was required for the heparin 12-mer to effec-
tively block exosome-cell interaction. In addition, heparin
12-mers that are devoid of eitherN-sulfation, 2-O-sulfation, or
6-O-sulfation were not as effective as fully sulfated 12-mer in
their ability to block exosome-cell interaction (data not shown).
Next, to determine whether fibronectin on the exosome sur-
face was binding to heparan sulfate on target cells, we utilized
reagents that would block that interaction. Fibronectin exists
either in a soluble dimeric form or an insoluble, fibrillar multi-
meric form (15). One monomer is composed by the repeat of
modular segments of 40–90 amino acids, termed type I, II, and
III repeat units (15). The heparin/heparan sulfate-binding
domain known as Hep-II, which is located in the type III seg-
ment, is the strongest heparin/heparan sulfate-binding site
within fibronectin. When target cells were preincubated with a
fragment of the fibronectin protein containing theHep-II bind-
ing site, it greatly diminished binding of CD63-RFP exosomes
as assessed by confocal microscopy and flow cytometry (Fig.
4A). A similar result was found when exosomes were labeled
with PKH67, a lipophilic dye that incorporates within lipid
membranes of vesicles (Fig. 4A). Next we utilized A32, an anti-
fibronectin monoclonal antibody specific for the Hep-II bind-
ing domain of fibronectin that blocks binding of fibronectin to
heparan sulfate (30). Preincubation of this antibody with exo-
somes inhibited their interaction with target cells, thereby con-
firming the role of the Hep-II domain in exosome-target cell
interaction (Fig. 4B). It is important to note that antibody A32
binds to fibronectin in a heparin/heparan sulfate-dependent
manner. Previous work demonstrated that heparin-induced
conformational changes in fibronectin increases the binding of
A32 to fibronectin (31). Thus it is possible that binding of
fibronectin to heparan sulfate on the surface of exosomes
increases the availability of epitopes for A32, thereby contrib-
uting to the effectiveness of A32 inhibition of exosome-cell
interactions.
Interaction of Myeloma Patient-derived Exosomes with Tar-
get Cells Is Mediated by Fibronectin Binding to Heparan
Sulfate—To determine whether the above in vitro findings are
relevant in humans, exosomes from the sera of three treatment
naïve multiple myeloma patients were isolated using an Exo-
Quick isolation kit and further purified using anti-CD63 linked
to magnetic beads. Characterization of the purified particles by
nanoparticle tracking revealed that they ranged in size from 50
to 200 nm, with the majority of particles smaller than 150 nm,
consistent with the size range of exosomes (Fig. 5A). ELISA
revealed that fibronectin was present on the exosomes from all
three myeloma patients examined (Fig. 5B). Interestingly, exo-
somes isolated from the serum of healthy controls also had
fibronectin on their surface, indicating that the mechanism we
describe may be relevant to exosomes secreted by both tumor
and normal cells (data not shown). Further characterization by
flow cytometry of exosomes from one of the myeloma patients
demonstrated that both syndecan-1 and fibronectin were on
the exosome surface (Fig. 5C). As was found with exosomes
secreted by the CAG myeloma cell line (Fig. 1), enzymatic
removal of heparan sulfate from the patient exosomes greatly
diminished the amount of fibronectin associated with exo-
somes (Fig. 5, D and E).
FIGURE3.Exosome-target cell interaction ismediatedbyheparan sulfate
chains on target cells. A, confocal microscopy analysis of polarized or non-
polarized CAGmyeloma cells following addition of CD63-RFP exosomes. Exo-
somes preferentially interact with heparan sulfate-rich uropods of polarized
cells but arewidely distributed on nonpolarized cells. B, depletion of heparan
sulfate chains on myeloma cells decreases exosome-target cell interaction.
RPMI-8226 cellswereuntreatedor treatedwithheparitinase andwashed, and
their interactions with exosomes were analyzed by confocal microscopy.
Right panel, quantitative data from a similar experiment analyzed by flow
cytometry. #, p 0.05 compared with no heparitinase treatment. C, heparin
and heparin oligosaccharides inhibit exosome-target cell interaction. CD63-
RFP exosomes were incubated with RPMI-8226 cells in the presence of hepa-
rin (10g/ml), fully sulfated heparin dodecasaccharide (12-mer) (100g/ml),
or Roneparstat (10 g/ml). Exosome alone is used as the control. After 2 h,
exosome-target cell interactionwas quantifiedby flow cytometry. The results
are themeans S.D. from three separate experiments. #, p 0.05 compared
with control.
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To determine whether fibronectin on exosomes from
patientsmediates interactionwith target cells, serum exosomes
were isolated, fluorescently labeled with PKH26 and incubated
with cells from a human bone marrow stromal cell line. The
exosomes readily interacted with stromal cells, and this was
inhibited by pretreatment of exosomes with monoclonal anti-
body A32 that binds to and blocks the Hep-II heparin-binding
domain of fibronectin (Fig. 5F). Together, these studies dem-
onstrate that exosomes in the circulation of myeloma patients
have fibronectin bound to their surface by heparan sulfate and
that the exosomal fibronectin interacts with heparan sulfate
chains on target cells to mediate the exosome-target cell
interaction.
The Fibronectin-mediated Interaction of Exosomes with Tar-
get Cells Impacts Target Cell Function—We have previously
demonstrated that exosomes secreted by the heparanase-high,
aggressivemyeloma cells promotesmyeloma cell spreading and
endothelial cell invasion. To explore this further and to deter-
mine whether the fibronectin-mediated interaction of exo-
somes with target cells impacted their function, we performed
two experiments. First, an antibody array was utilized to deter-
mine whether specific signaling events were initiated in the
target cells shortly after their interaction with exosomes. Exo-
somes secreted by aggressive (heparanase-high) myeloma cells
were incubatedwith RPMI-8226myeloma cells for 2 h, the cells
were extracted, and the extracts incubatedwith antibody arrays
to determine the level of tyrosine phosphorylation of specific
molecules within key signaling pathways. The results demon-
strated that cells incubatedwith exosomes have increased levels
of phosphorylated p38 and to a lesser extent phosphorylated
ERK (Fig. 6A). Further, to determinewhether the enhanced p38
activation induced by cells is dependent on the fibronectin-
heparan sulfate interactions, equal amounts of exosomes (100
g) from control and aggressive myeloma cells were added to
RPMI-8226 cells and analyzed for phosphorylated p38 by
Western blotting. Fig. 6B shows that aggressive exosomes
induces p38 activation in RPMI-8226, and this is inhibited
whenheparan sulfate chains are removed fromRPMI8226 cells.
These results demonstrate that enhanced docking of exosomes
to cells through a fibronectin-heparan sulfate interaction can
activate signaling pathways in myeloma cells. To determine
whether the up-regulation in p38 signaling was sufficient to
impact gene expression, we examined its downstream targets
DKK1 andMMP-9.Analysis by PCR revealed that transcription
of both DKK1 and MMP-9 were elevated in the cells following
interaction with exosomes (Fig. 6C). In a second approach, the
FIGURE 4. Fibronectin on exosomesbinds to heparan sulfate on target cells tomediate exosome-target cell interaction.A, heparin binding fragment of
the fibronectin protein inhibits exosome interaction. RPMI-8226 cells were untreated or treated with a heparin binding (Hep-II) 40-kDa fragment of purified
human plasma fibronectin for 1 h, washed, and then incubated for 2 hwith CD63-RFP exosomes or PKH67-labeled exosomes. The cells were thenwashed and
fixed, and exosome interactions were analyzed by confocal microscopy. Quantitative data from a similar experiment, using CD63-RFP exosomes, were
analyzed by flow cytometry (right panel). #, p 0.05 compared with control. B, a monoclonal antibody (A32) that binds to the Hep-II domain of fibronectin
decreases exosome-target cell interaction. CD63-RFP exosomeswere preincubatedwith A32 antibody for 1 h and then added to RPMI-8226 cells. After 2 h, the
cells were fixed and analyzed by confocal microscopy. Quantitative data from similar experiment were analyzed by flow cytometry (right panel). #, p 0.05
compared with control. FN, fibronectin.
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impact of exosome-endothelial cell interaction on endothelial
cell invasion was examined. Exosomes were preincubated with
antibody to the Hep-II heparin-binding domain of fibronectin,
and their ability to promote human umbilical vein endothelial
cell invasion throughMatrigel-coated chambers was compared
with exosomes not exposed to antibody. The results indicate
that blocking of fibronectin with the antibody significantly
inhibited endothelial invasion (Fig. 6D). Together, these studies
indicate that fibronectin-mediated interaction of exosomes
with target cells can significantly impact target cell behavior.
Discussion
This work demonstrates a novel mechanism through which
exosomes secreted by cancer cells interact with target cells. The
data indicate that heparan sulfate on the exosome surface cap-
tures fibronectin, and when a target cells is encountered, the
exosomal fibronectin binds to heparan sulfate proteoglycans
present on the target cell surface (Fig. 7). This model is sup-
ported by studies utilizing exosomes from both myeloma cell
lines andmyeloma patient sera. Although we cannot verify that
all the vesicles isolated from patients were derived from tumor
cells, a relatively high number of the isolated exosomes were
CD138-positive (Fig. 5), in line with the fact thatmostmyeloma
cells express high levels of this marker (32). In addition, most of
the patient-derived exosomes had fibronectin on their surface
that could be removed by treatment with heparan sulfate
degrading enzyme. Further, blocking the Hep-II domain with
antibodies inhibited binding of the patient exosomes to target
cells (Fig. 5). Together, these data support the notion that
fibronectin on circulating exosomes from myeloma patients
mediates their binding to heparan sulfate on target cells.
Because of its abundance on cell surfaces, within the extracel-
lular matrix and in the serum, we speculate that fibronectin is
not restricted to tumor-derived exosomes but is present on the
surface of exosomes derived from many cell types in both nor-
mal and pathological settings. In addition, it seems likely that
exosome-fibronectin interaction may also facilitate exosome
binding to extracellular matrix by binding to collagens or hepa-
ran sulfate trappedwithin thematrix. This is important because
tumor-derived exosomes have been shown to bind components
of the extracellular matrix where they can promotematrix deg-
radation and tumor cell invasion and motility (33).
Interestingly, and in support of our finding of fibronectin on
the surface of exosomes, it was recently demonstrated that exo-
somes present in blood plasma of normal human subjects can
be isolated on heparin affinity beads (34), clearly demonstrating
that a ligand for heparan sulfate exists on the surface of circu-
lating exosomes.Moreover, heparin has been shown to directly
interact with extracellular vesicles and heparin inhibits vesicle
binding to target cells (11, 14). In another study, exogenous
heparin or treatment of cells with heparan sulfate degrading
enzymes reduced exosome-target cell interaction by 50%
(12). However, in contrast to our findings that point to a role for
FIGURE 5. Fibronectin on exosomes isolated from multiple myeloma
patients facilitates interaction with bone marrow stromal cells. A,
characterization of exosomes from serum of treatment naïve multiple
myeloma patients. Exosomes were purified from serum of myeloma
patients by ExoQuick precipitation followed by isolation using anti-CD63
conjugated beads. Particle size was analyzed by nanoparticle tracking
using a NanoSight 300. Histogram shows two lines representing duplicate
analyses. B, ELISA quantification of the levels of fibronectin in exosomes
isolated from serum of three myeloma patients. C, syndecan-1 and
fibronectin are present on the surface of myeloma patient derived exo-
somes. Exosomes purified from the serum of myeloma patients using Exo-
Quick precipitation followed by anti-CD63 magnetic bead isolation were
subjected to flow cytometry analysis using an affinity-purified polyclonal
goat anti-syndecan-1 IgG antibody (blue) or mouse monoclonal PE-conju-
gated anti-fibronectin antibody (blue). Normal goat IgG and mouse IgG1
isotype were used as control (red), respectively. Note that syndecan-1
(core protein) was detected on the surface of exosomes only after removal
of heparan sulfate chains by heparitinase treatment to expose the
epitope. D and E, removal of heparan sulfate chains removes most of the
fibronectin from exosomes isolated from the serum of myeloma patients.
Exosomes isolated from patient serum were either not treated or treated
with heparitinase, and fibronectin levels were quantified by ELISA (D) and
compared by Western blot (E). #, p  0.05 compared with heparitinase
untreated exosomes. F, A32 antibody against the Hep-II domain of
fibronectin blocks the interaction of patient-derived exosomes with bone
marrow stromal cells. Exosomes isolated from the serum of a myeloma
patient were labeled with PKH26 (red) dye, preincubated with or without
A32 antibody for 1 h, and allowed to bind HS-5 human bone marrow
stromal cells. After 2 h cells were fixed, and images were analyzed by
confocal microscopy. FN, fibronectin.
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exosomal fibronectin in exosome-target cell interactions, these
prior studies failed to identify the ligand present on the exo-
some that was interacting with heparan sulfate on the cell
surface.
Although fibronectin has been detected by mass spectros-
copy as cargo within exosomes frommany cell sources (35, 36),
to our knowledge, our data provide the first evidence that
fibronectin is mediating exosome-target cell interaction.
Fibronectin has been shown to be present on the surface of
exosomes secreted by trophoblasts where it associates with
macrophages and induces their expression of IL-1 (37). This
occurs without exosome internalization and is likely mediated
through the interaction of exosome fibronectin with integrin
surface receptors on the macrophages. In addition, it was
recently demonstrated that HT1080 fibrosarcoma cells deposit
exosomes to the substrata that are assessable to the basal cell
surface. These exosomes have surface fibronectin that helps
support cell adhesion and accelerate cell migration (38). In this
case, it was demonstrated that50%of the fibronectin could be
displaced from exosomes by incubation with the RGD peptide,
indicating that at least some of the fibronectinwas bound to the
exosome via integrins. Similarly, fibronectin was found on the
surface of exosomes isolated from ex vivo cultured 4T1 breast
cancer cells, and those exosomes could stimulate tumor cell
migration via activation of integrins (39). However, none of the
above studies examined whether the fibronectin on the exo-
somes being studied associated with heparan sulfate present
either on the exosome or on the cell surface. Interactions
between fibronectin and heparan sulfate could explain why
only half the fibronectin was displaced from the fibrosarcoma-
derived exosomes by the RGD peptide (38). Interestingly,
althoughwe did not explore whether integrins were involved in
the targeting of myeloma-derived exosomes to cells, we found
that removal of heparan sulfate from exosomes did remove
most of the exosome associated fibronectin (Figs. 2 and 5). This
FIGURE 6. Exosome-target cell interaction mediated by fibronectin
impacts cell behavior.A, exosome interactionwithRPMI-8226 cells activates
p38 and ERK signaling. An antibody array that simultaneously examines the
phosphorylation levels of 43 different protein kinases was utilized to deter-
mine what signaling pathways were activated when myeloma-derived exo-
somes interacted with target cells. RPMI-8226 cells were incubated with or
without exosomes isolated from aggressive myeloma cells (CAG cells
expressing high heparanase), cell lysates were exposed to membranes, and
the membranes were probed with a phosphotyrosine specific antibody.
Phosphorylated p38 and ERK (circled) were enhanced in cells incubated with
the exosomes. The different phospho kinases that are activated in RPMI-8226
cells independentof theadditionof exosomesare shownbyarrows.Duplicate
dotsat the corners representphosphotyrosinepositive controls.B, RPMI-8226
cells were treated with exosomes (100 g/ml) secreted by control or aggres-
sivemyeloma cells for 20min and analyzed for phosphorylated p38 byWest-
ern blot. Total p38 serves as the loading control. To determine the role of cell
surface heparan sulfate inmediating exosome-induced signaling, RPMI-8266
cells were treated with bacterial heparitinase for 2 h prior to the addition of
exosomes from aggressive myeloma cells. C, MMP-9 and DKK1, two down-
stream target genes of activated p38, are up-regulated following the interac-
tion of myeloma-derived exosomes with the RPMI 8226 cells. RPMI 8266
myeloma cells were incubated with or without exosomes, and DKK1 and
MMP-9mRNA expression in these cells was assessed using real time PCR and
normalized using actin expression. *, p  0.05 compared with no exosome
addition. D, 10 g of CD63-RFP exosomes from aggressive CAG cells were
added to endothelial cells in the presence or absence of A32 antibody, and
the number of cells that invaded through theMatrigel-coated chamber over-
night was determined. The data aremeans S.D. from three separate exper-
iments. #, p  0.01 compared with no exosome addition; ¥, p  0.05 com-
pared with exosomes only.
FIGURE 7. Model of exosome-target cell interaction mediated by
fibronectin. Step 1, fibronectin (FN) is captured on the surface of exosomes
by heparan sulfate proteoglycans (HSPG). Step 2, fibronectin, on exosomes
binds to heparan sulfate (HS) on the surface of the target cell. Step 3, removal
of exosome heparan sulfate or cell surface heparan sulfate with heparitinase,
addition of exogenous heparin or heparin mimetics, addition of Hep-II
domain-containing fragment of fibronectin, or exposure to antibody against
the Hep-II domain of fibronectin dramatically diminishes exosome interac-
tion with target cells.
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suggests that heparan sulfate is responsible for binding most of
the fibronectin to the surface of these myeloma-derived exo-
somes. Notably, removal of heparan sulfate from target cells
only reduced exosomebinding by50% (Fig. 3), and interfering
with theHep-II domain of fibronectin (Fig. 4) also only partially
inhibited binding of exosomes. This raises the possibility that
integrin receptors on target cells may also contribute to the
fibronectin-mediated targeting.
Our results indicate that heparan sulfate plays a dual role in
the interaction between exosomes and cells, first by capturing
fibronectin on the exosome surface and then through interac-
tion of exosome fibronectin with heparan sulfate on the surface
of cells. Because heparan sulfate is ubiquitously expressed on
cell surfaces, the mechanism we describe here is likely not
mediating targeting of exosomes to specific cell types. Rather,
this may be a general mechanism that mediates initial binding
of exosomes to most cells. However, some specificity of exo-
some binding to cells could be conferred through the structure
of cell surface heparan sulfate chains. For example, it was dem-
onstrated that cells lacking heparan sulfate 2-O- or -N-sulfation
exhibited reduced exosome binding compared with controls
(13). It was previously demonstrated that after binding of exo-
somes to cells, cell surface heparan sulfate proteoglycans were
internalized by cells thereby mediating exosome uptake (13).
Thus cell surface heparan sulfate proteoglycans appear to be
internalizing receptors for exosomes rather than just cell sur-
face attachment sites. Although the mechanism of release of
exosome cargo within cells is not clear, once internalized, exo-
somesmay fuse with the delimitingmembrane of the endocytic
compartment and deliver the cargo to the cytosol of target cells
(40). It is not known whether heparan sulfate proteoglycans
play a role in exosome cargo release.
In regard to heparan sulfate on exosomes, it has been shown
that the syndecan heparan sulfate proteoglycans, through for-
mation of a molecular complex with syntenin and ALIX, help
drive exosome formation (41).We found that heparanase stim-
ulated exosome secretion in myeloma cells (9), and further
studies by Roucourt et al. (42) recently confirmed our findings
and demonstrated that heparanase, by trimming the heparan
sulfate chains of syndecan, activates the syndecan-syntenin-
ALIX pathway. Interestingly, heparanase causes more synde-
can-1 to be recruited to exosomes (9, 42), and in the present
work, we discovered that this results in a greater amount of
fibronectin associating with the exosome surface leading to
enhanced exosome-target cell interaction (Fig. 1). Thus our
current findings demonstrate that the importance of the hepa-
ranase/syndecan axis in regulating the biology of exosomes is
not restricted solely to exosome biogenesis and cargo content
but also impacts exosome-target cell interaction, a key step in
the ability of exosomes to regulate cell behavior.
Although we find that heparan sulfate on myeloma-derived
exosomes plays an important role in their interaction with tar-
get cells, this may not be a universal mechanism used by all
exosomes. For example, using exosomes isolated from theU-87
MG glioblastoma cell line, it was concluded that although both
syndecan and glypican proteoglycans were associated with the
exosomes, heparan sulfate present on the exosome was not
involved in interactions with target U-87 MG cells (12). This
does not preclude the possibility that fibronectin is involved,
because fibronectin in this setting, rather than being bound by
heparan sulfate chains, could be attached to exosomes predom-
inantly via integrins present on the exosome surface. Another
possibility is thatmyeloma cell-derived exosomes have a higher
level of heparan sulfate and/or fibronectin on their surface that
drives the exosome-cell interaction as compared with the glio-
blastoma-derived exosomes. This would be consistent with our
observation that exosomes having low levels of heparan sulfate
and fibronectin do not interact with cells as avidly as exosomes
having higher levels of thesemolecules (Fig. 1). This suggests, at
least in the case of the myeloma cells, that the capacity of exo-
somes to interact with target cells is regulated by the amount of
heparan sulfate on the exosome surface.
Wedemonstrate that the exosome-target cell interaction can
be blocked by enzymatic removal of heparan sulfate from either
the exosome or target cell, by exposure to heparin/heparin ana-
logues that interfere with heparan sulfate/fibronectin interac-
tions, by antibody against the Hep-II protein domain within
fibronectin that binds to heparan sulfate, or by addition of
excess fragments of the fibronectin protein that contain the
Hep-II domain. These findings not only support our model of
fibronectin-heparan sulfate-mediated interaction of exosomes
with cells, but also expose multiple ways in which that interac-
tion could be attacked in patients for therapeutic benefit. Of
particular importance is the finding that heparin, a synthetic
fully sulfated 12-mer heparin mimetic, and heparin-derived
Roneparstat are all capable of significantly inhibiting targeting
of exosomes to cells. Importantly, unlike heparin, both the
12-mermimetic and Roneparstat lack significant anticoagulant
activity and thus can be delivered to patients at high doses,
thereby disrupting or preventing exosome-target cell interac-
tions. These findings reveal a previously undescribed mecha-
nism of action for this class of drugs and provide further ration-
ale for their investigation in clinical trials.
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